To test this hypothesis, cathepsin K transgenic mice were challenged with bleomycin and their lung cell- and tissue-specific cathepsin K expression, lung fibrosis, and lung function was compared with that of bleomycin-treated wild-type mice. The gene discussed is CTSK; the disease is pulmonary fibrosis.